Background In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of
multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current …

SETTING: Tuberculosis (TB) program, Damien Foundation Projects, Bangladesh.
OBJECTIVE: To summarize the outcome and its determinants of the first treatment for …

Multidrug-resistant (MDR) tuberculosis is a growing clinical and public-health concern. To
evaluate existing evidence regarding treatment regimens for MDR tuberculosis, we used a …

SETTING: Nine countries in West and Central Africa. OBJECTIVE: To assess outcomes and
adverse drug events of a standardised 9-month treatment regimen for multidrug-resistant …

Multidrug-resistant (MDR) tuberculosis (TB) is a threat to global TB control, as suboptimal
and poorly tolerated treatment options have resulted in largely unfavourable outcomes for …

In the last decade, multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at
least isoniazid and rifampicin) has become an epidemiological issue of first priority at the …

SETTING: Individualised regimens based on drug susceptibility test results, generally used
to treat multidrug-resistant tuberculosis (MDR-TB), require often unavailable expertise and …

Abstract Background Cohort studies in Bangladesh showed promising cure rates among
patients with multidrug-resistant tuberculosis who received existing drugs in regimens …

Multidrug-resistant tuberculosis (MDR-TB) presents an increasing threat to global
tuberculosis control. Many crucial management issues in MDR-TB treatment remain …

About ten years ago, the first results of the so-called “Bangladesh regimen”, a short regimen
lasting nine months instead of 20 months, revolutionized multidrug-resistant tuberculosis …